Keros Therapeutics (KROS) Retained Earnings (2019 - 2025)
Keros Therapeutics posted quarterly Retained Earnings of -$481.8 million for Q4 2025, up 15.3% year-on-year from -$417.8 million in Q4 2024, and down 5.12% on a QoQ basis from -$458.3 million in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Retained Earnings data on file, last reported at -$481.8 million in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings rose 15.3% year-over-year to -$481.8 million; the trailing twelve-month figure through Dec 2025 stood at -$481.8 million (up 15.3% YoY), and the FY2025 full-year result was -$481.8 million, up 15.3% from the prior year.
- Retained Earnings for Q4 2025 stood at -$481.8 million, down from -$458.3 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$80.9 million in Q1 2021 and bottomed at -$568.8 million in Q4 2024.
- The 5-year median for Retained Earnings is -$321.5 million (2023), against an average of -$312.7 million.
- The widest annual swing landed in 2021, when Retained Earnings plunged 156.47%; it then gained 15.3% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$123.8 million in 2021, then sank by 84.59% to -$228.4 million in 2022, then slumped by 66.97% to -$381.4 million in 2023, then sank by 49.12% to -$568.8 million in 2024, then rose by 15.3% to -$481.8 million in 2025.
- The last three Retained Earnings figures came in at -$481.8 million (Q4 2025), -$458.3 million (Q3 2025), and -$451.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -481.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -481.77 Mn |
| Sep 30, 2025 | -458.30 Mn |
| Jun 30, 2025 | -451.02 Mn |
| Mar 31, 2025 | -420.33 Mn |
| Dec 31, 2024 | -568.78 Mn |
| Sep 30, 2024 | -522.75 Mn |
| Jun 30, 2024 | -469.80 Mn |
| Mar 31, 2024 | -424.54 Mn |
| Dec 31, 2023 | -381.43 Mn |
| Sep 30, 2023 | -341.18 Mn |
| Jun 30, 2023 | -301.74 Mn |
| Mar 31, 2023 | -264.24 Mn |
| Dec 31, 2022 | -228.43 Mn |
| Sep 30, 2022 | -198.72 Mn |
| Jun 30, 2022 | -175.21 Mn |
| Mar 31, 2022 | -147.94 Mn |
| Dec 31, 2021 | -123.76 Mn |
| Sep 30, 2021 | -116.82 Mn |
| Jun 30, 2021 | -96.52 Mn |
| Mar 31, 2021 | -80.90 Mn |
| Dec 31, 2020 | -65.01 Mn |
| Sep 30, 2020 | -54.34 Mn |
| Jun 30, 2020 | -42.30 Mn |
| Mar 31, 2020 | -31.54 Mn |
| Dec 31, 2019 | -19.65 Mn |